EU-OPENSCREEN (EU-OS), the European Research Infrastructure of Open Screening Platforms for Chemical Biology, builds a distributed organization of national screening and chemistry facilities, a common database, and a central headquarter that manages the joint compound collection and coordinates project flow and training. It provides world-class services to academia and industry in the fields of small molecule screening and medicinal chemistry. EU-OS developed its concept and business plan during the preparatory phase and has received information on the Commission Implementing Decision on setting up the EU-OS European Research Infrastructure Consortium (EU-OSERIC) in March 2018.
In 2018, EU-OS will start its ERIC operations with seven founding members and one observer. EU-OS will promote the rich chemical knowledge of Europe and enabling systematic studies of the bioactivities of a larger collection of compounds leading to ground-breaking insights into cellular and organismal metabolic or signalling pathways. After careful consideration of IPR from all stakeholders involved, all results will eventually become available to the public. EU-OS will thereby also play an increasingly important role in facilitating the drug discovery process in Europe. In addition, it also has a great potential for innovative development of biomarkers and other diagnostics.
By carefully considering the recommendations of the Long-term Sustainability Action Plan of the EC and ESFRI, EU-OS will utilize EU-OS-DRIVE to specifically promote measures for
EU-OS-DRIVE will further help the EU-OS-ERIC to deliver its added-value via constant re-use of generated data and tools by users across the globe and to support the competitiveness of European life science industries.
Duration: February 1st 2019 – January 31st2023
Call (part) identifier: H2020-INFRADEV-2018-1
Topic INFRADEV-03-2018-2019 - Individual support to ESFRI and other world-class research infrastructures
+49 (0)30 9489 2424
Additional information on the project will follow soon.
This project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823893.